CytomX Therapeutics, Inc.
151 Oyster Point Blvd., Suite 400
South San Francisco, CA 94080
February 8, 2019
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: | Joseph McCann, Staff Attorney |
Re: | CytomX Therapeutics, Inc. |
Registration Statement on Form S-3 (Registration No. 333-228203) |
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration by the Securities and Exchange Commission of the effective date of the above-referenced Registration Statement on Form S-3 (the Registration Statement) of CytomX Therapeutics, Inc. We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on February 11, 2019, or as soon as practicable thereafter.
Thank you for your assistance in this matter.
Very truly yours, | ||
CytomX Therapeutics, Inc. | ||
By: | /s/ Lloyd A. Rowland | |
Lloyd A. Rowland | ||
General Counsel |
CC: | Sean A. McCarthy, CytomX Therapeutics, Inc. |
Debanjan Ray, CytomX Therapeutics, Inc. |
Mark V. Roeder, Latham & Watkins LLP |